Cell Line Development Market Research Report Forecast till 2027

$4,950$7,250

The global cell line development market is evaluated to exhibit a significant CAGR of 11.3% during the review period to reach USD 10,829.9 million by the end of 2027.

SKU: MRFR220278 Category: Tag:

Description

Cell Line Development Market Research Report Forecast till 2027

Market Synopsys
The global cell line development market is evaluated to exhibit a significant CAGR of 11.3% during the review period to reach USD 10,829.9 million by the end of 2027.

Cell Line Development is used for drug target recognition and production of biologic drugs. These cell line development methods are used in Cell surface expression screening, Cell viability, Clone productivity screening and titer, Comparison of traditional cloning methods with f.sight, COVID-19 and Infectious Disease Research, Monoclonality, Single cell sorting etc.

the global market growth is driven by the growing demand for monoclonal antibodies, expanding biotechnology industry, increasing vaccine production worldwide. However, the complicated method for developing stable and authentic cell lines, need of skilled workers and the high maintenance cost is expected to restrain the global market during the review period.

The global cell line development market is expected to witness a significant market expansion during the review period. The rising application of cell lines in biotech & pharmaceutical companies and hospitals and the increasing incidences of chronic diseases are set to accelerate the global market during the review period.

In this manner, the rising reception of mammalian hotspots for the development of monoclonal antibodies and the rising interest for communicating complex proteins like people are expected to give huge learning experiences.

Market Segmentation
Global Cell Line Development market is classified based on type, product source, application, and region.

The type of segment classifies the market into Primary Cell Lines, Hybridomas, Recombinant Cell Line, and Continuous Cell Lines. Based on Product the market has been divided into Equipment and Media and Reagents.

The Source type is bifurcated into Mammalian Cells and Non-Mammalian Cells, the Non-Mammalian type is further divided into Insects and Amphibians.

The Application segment is categorized into Bio-production, drug discovery, Tissue Engineering, and others. Bio-production category is further divided into antibody production, enzyme production, hormone production, and others. The antibody production type is again bifurcated as mono and multi types.

Regional Analysis
The examination research centers across North America are progressively modernizing their methodology and utilizing cell line development instruments for immunizer creation, drug digestion and cytotoxicity, tissue designing, immunization creation, concentrating on quality articulation, creation of helpful proteins, and different purposes.

In addition, the market in the locale is driven by the rising R&D in the drug and biopharmaceutical industry, zeroing in on cell line development. In October 2019, ATCC sent off another validation administration that assists scientists with affirming the character of mouse cell lines without any problem. The help was created in alongside the National Institutes for Standards and Technology.

Asia-Pacific is expected to be the quickest developing provincial market over the appraisal time frame because of quickly further developing medical services framework, expanding interest for monoclonal antibodies to treat different illnesses, for example, myocardial illness and malignant growth, utilization of cell line for immunization development by the organizations, and government support in controlling biotechnology items around here.

Major Players
The key companies associated with a global cell line development market research are Pfizer (US), Novartis (Switzerland), Cellectis (France), and bioMérieux SA (France)

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING R&D IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
4.2.2 INCREASING APPLICATION OF CELL LINES IN BIOTECH & PHARMACEUTICAL COMPANIES AND HOSPITALS
4.2.3 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
4.3 RESTRAINTS
4.3.1 HIGH MAINTENANCE COSTS AND DEARTH OF SKILLED STAFF
4.3.2 COMPLEXITY INVOLVED IN DEVELOPING STABLE AND AUTHENTIC CELL LINES
4.4 OPPORTUNITY
4.4.1 RISING ADOPTION OF MAMMALIAN SOURCES FOR ANTIBODY PRODUCTION
4.4.2 TECHNOLOGICAL INNOVATION IN CELL LINE DEVELOPMENT
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 SALES & MARKETING
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CELL LINE DEVELOPMENT MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON DEMAND
5.3.3 IMPACT ON SUPPLY
5.3.4 IMPACT ON TRADE (IMPORT/EXPORT)
5.3.5 IMPACT ON KEY PLAYERS
6 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 EQUIPMENT
6.3 REAGENTS & MEDIA
7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY SOURCE
7.1 OVERVIEW
7.2 MAMMALIAN
7.3 NON-MAMMALIAN
7.3.1 AMPHIBIANS
7.3.2 INSECTS
8 GLOBAL CELL LINE DEVELOPMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 RECOMBINANT CELL LINES
8.3 HYBRIDOMAS
8.4 CONTINUOUS CELL LINES
8.5 PRIMARY CELL LINES
9 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 BIOPRODUCTION
9.2.1 MARKET TRENDS AND COMPARATIVE GROWTH RATE OF BISPECIFICS/MULTISPECIFICS AND CELL LINE DEVELOPMENT MARKET
9.2.2 ANTIBODY PRODUCTION
9.2.2.1 MONO
9.2.2.2 BI/MULTI
9.2.3 ENZYME PRODUCTION
9.2.4 HORMONE PRODUCTION
9.2.5 OTHERS
9.3 DRUG DISCOVERY
9.4 TISSUE ENGINEERING
9.5 OTHERS
10 GLOBAL CELL LINE DEVELOPMENT MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 SWITZERLAND
10.3.7 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 GLOBAL CELL LINE DEVELOPMENT MARKET: COMPANY SHARE ANALYSIS
11.3 COMPETITIVE BENCHMARKING
11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
11.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
11.6 KEY DEVELOPMENT ANALYSIS
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.7.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
11.7.2 MERGER/ACQUISITION
11.7.3 PARTNERSHIP/ AGREEMENT
11.7.4 EXPANSION/ INVESTMENT
11.8 FINANCIAL MATRIX
11.8.1 SALES (USD MILLION), 2020
11.8.2 R&D EXPENDITURE (USD MILLION), 2020
12 COMPANY PROFILES
12.1 LONZA GROUP
12.1.1 COMPANY OVERVIEWS
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 SELEXIS SA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 THERMO FISHER SCIENTIFIC INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS.
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 WUXI BIOLOGICS
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 RENTSCHLER BIOPHARMA SE
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 HORIZON DISCOVERY LTD
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 SARTORIUS AG
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 MERCK KGAA
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENT
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS

Companies Mentioned

Pfizer (US), Novartis (Switzerland), Cellectis (France), and bioMérieux SA (France)

Reviews

There are no reviews yet.

Be the first to review “Cell Line Development Market Research Report Forecast till 2027”

[class^="wpforms-"]
[class^="wpforms-"]